Last updated on June 2019

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Brief description of study

The primary purpose of this study is to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

Clinical Study Identifier: NCT03093480

Find a site near you

Start Over

Children's Hospital Los Angeles

Los Angeles, CA United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Michigan State University

East Lansing, MI United States
  Connect »

El Paso Children's Hospital

El Paso, TX United States
  Connect »

Cook Children's Medical Center

Fort Worth, TX United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

St Thomas' Hospital

London, United Kingdom
  Connect »